MBX-8025

DRUG2 trials

Sponsors

Gilead Sciences, CymaBay Therapeutics Inc

Conditions

Homozygous familial hypercholesterolemiaHyperlipidemia

Phase 2

Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol

CompletedNCT00701883

Gilead SciencesHyperlipidemia

Start: 2007-08-31End: 2008-08-31Updated: 2015-06-12

A 12-week, open-label, dose-escalating, phase 2 study to evaluate the effects of MBX-8025 in patients with Homozygous Familial Hypercholesterolemia (HoFH) (study CB8025-21427)

CymaBay Therapeutics IncHomozygous familial hypercholesterolemia

Target: 3Updated: 2024-02-28